Corporate News – Market Update for Hyxl (300886.SZ)
Hyxl (300886.SZ) finished the trading day unchanged, with a 0 % movement over the 24‑hour period ending at 07:44 PM Central Europe on Friday 23 April 2026. At the close, one share of Hyxl traded at CNY 23.29 on the primary exchanges. The company’s share supply stands at 77.4 million, giving it a market capitalisation of CNY 1.7 billion. In the past 24 hours, roughly CNY 20.6 million worth of Hyxl shares exchanged hands, a modest volume that reflects the flat price action. Compared with the close at the end of the previous month, Hyxl has declined by 11.84 %. The 200‑day simple moving average sits at CNY 22.70, placing the current price just above this technical benchmark. The 52‑week high and low for Hyxl are CNY 31.99 (19 November 2025) and CNY 18.60 (21 July 2026), respectively.
Q3 and Year‑to‑Date Performance (2026)
Hyxl recently released its third‑quarter and year‑to‑date results for 2026. Revenue for the third quarter surged, driven by an expanded market reach and stronger sales of core flavour products. Net profit, meanwhile, registered a substantial increase, pushing earnings per share higher. Over the first nine months of the year, revenue grew at a moderate pace; however, net profit slipped slightly, largely due to elevated financial costs associated with currency fluctuations. Operating cash flow saw a pronounced rise, reflecting increased cash inflows from sales activity.
A notable highlight of the report is the investment in a new 1,300‑ton flavour production line. This capital expenditure has increased the company’s fixed‑asset base and triggered a rise in short‑term borrowing. The management narrative suggests that, while capital deployment is ongoing, short‑term profitability remains robust.
24‑Hour Performance of Peer Stocks
| Symbol | Price (CNY) | % Change | Market Cap (CNY) | P/E Ratio |
|---|---|---|---|---|
| Avcon Information Technolo (300074.SZ) | 3.62 | 0 % | 2 billion | – |
| Shandong Buchang Pharmaceu (603858.SS) | 14.8 | 0 % | 2.2 billion | 66.49 |
| Improve Medical (300030.SZ) | 6.3 | 0 % | 2 billion | 60.97 |
| Shanghai Sanmao Enterprise (600689.SS) | 11.36 | 0 % | 2 billion | 166.47 |
| Zhejiang Orient G (600120.SS) | 4.54 | 0 % | 2.1 billion | 10.77 |
All of these peers exhibited flat price action over the past 24 hours. Shandong Buchang Pharmaceutical has actively engaged investors through the “World Investor Week” initiative, issued educational communications on the risks of AI‑driven marketing fraud, and urged investors to verify platform legitimacy before engaging in cross‑border transactions. Shanghai Sanmao Enterprise’s shares benefited from net capital inflows amid a broader market that experienced selective gains in consumer goods and technology sectors, despite sector‑wide volatility.
This article presents a concise overview of Hyxl’s latest market performance and recent financial results, contextualised within the broader performance of comparable listed companies.